1. Home
  2. CBAT vs CCCC Comparison

CBAT vs CCCC Comparison

Compare CBAT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBAT
  • CCCC
  • Stock Information
  • Founded
  • CBAT 1999
  • CCCC 2015
  • Country
  • CBAT China
  • CCCC United States
  • Employees
  • CBAT 1463
  • CCCC N/A
  • Industry
  • CBAT Industrial Machinery/Components
  • CCCC Biotechnology: Pharmaceutical Preparations
  • Sector
  • CBAT Miscellaneous
  • CCCC Health Care
  • Exchange
  • CBAT Nasdaq
  • CCCC Nasdaq
  • Market Cap
  • CBAT 102.5M
  • CCCC 104.4M
  • IPO Year
  • CBAT N/A
  • CCCC 2020
  • Fundamental
  • Price
  • CBAT $1.16
  • CCCC $1.43
  • Analyst Decision
  • CBAT
  • CCCC Buy
  • Analyst Count
  • CBAT 0
  • CCCC 3
  • Target Price
  • CBAT N/A
  • CCCC $12.00
  • AVG Volume (30 Days)
  • CBAT 310.3K
  • CCCC 1.3M
  • Earning Date
  • CBAT 08-08-2025
  • CCCC 07-31-2025
  • Dividend Yield
  • CBAT N/A
  • CCCC N/A
  • EPS Growth
  • CBAT N/A
  • CCCC N/A
  • EPS
  • CBAT 0.00
  • CCCC N/A
  • Revenue
  • CBAT $152,731,078.00
  • CCCC $39,783,000.00
  • Revenue This Year
  • CBAT $28.79
  • CCCC N/A
  • Revenue Next Year
  • CBAT $36.77
  • CCCC N/A
  • P/E Ratio
  • CBAT $12,978.44
  • CCCC N/A
  • Revenue Growth
  • CBAT N/A
  • CCCC 98.56
  • 52 Week Low
  • CBAT $0.57
  • CCCC $1.09
  • 52 Week High
  • CBAT $1.45
  • CCCC $7.66
  • Technical
  • Relative Strength Index (RSI)
  • CBAT 64.33
  • CCCC 50.43
  • Support Level
  • CBAT $1.07
  • CCCC $1.36
  • Resistance Level
  • CBAT $1.23
  • CCCC $1.63
  • Average True Range (ATR)
  • CBAT 0.06
  • CCCC 0.14
  • MACD
  • CBAT -0.00
  • CCCC -0.00
  • Stochastic Oscillator
  • CBAT 71.43
  • CCCC 38.10

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: